|Year : 2020 | Volume
| Issue : 10 | Page : 2121
Commentary: Pregnancy hormone to control intraocular pressure?
John D Akkara1, Anju Kuriakose2
1 Department of Ophthalmology, Little Flower Hospital and Research Centre, Angamaly; Department of Glaucoma, Westend Eye Hospital, Cochin, Kerala, India
2 Department of Retina, Aravind Eye Hospital, Chennai, Tamil Nadu, India
|Date of Web Publication||23-Sep-2020|
Dr. John D Akkara
Department of Glaucoma, Westend Eye Hospital, Kacheripady, Cochin - 682 018, Kerala
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Akkara JD, Kuriakose A. Commentary: Pregnancy hormone to control intraocular pressure?. Indian J Ophthalmol 2020;68:2121
Pregnancy and the body
Pregnancy is a time of profound physiological changes in a woman's body. In addition to the circulatory system changes and rearrangements in the abdomen, there are massive fluctuations in the hormonal levels, potentially leading to changes in each and every organ in her body.
Pregnancy and the eye
Studies in pregnant women have shown that there is increased retention of water in the corneal stroma probably due to hormonal changes. Central Corneal Thickness (CCT), Anterior Chamber Depth (ACD), and Anterior Chamber Angle (ACA) are higher in the third trimester of pregnancy than postpartum. There is increased plasticity of the anterior chamber before delivery, which presumably helps to counteract the excess intraocular pressure (IOP) rise during the second stage of labor.
Pregnancy, IOP, and glaucoma
During pregnancy, IOP is reduced in healthy women. Mechanisms proposed to include progesterone and relaxin induced increased aqueous outflow facility, decreased episcleral venous pressure, and gestational metabolic acidosis. For glaucoma patients in pregnancy, though a majority still shows the reduction in IOP, it can increase or remain stable too. This variable course of IOP may be due to the interplay of various hormones in pregnancy. Visual fields have also shown a variable outcome in pregnancy with a study showing progression in IOP or visual fields in 35% of the subjects.
Glaucoma Medications in Pregnancy
Though topical medications are one of the easiest ways to control IOP, their risks in pregnancy have not been well established. There are currently no glaucoma medications in the United States Food and Drug Administration (FDA) Category A, which implies safety demonstrated in human trials. Brimonidine is classified under Category B, which presumes safety based on animal studies. Beta Blockers, Carbonic Anhydrase inhibitors, parasympathomimetics, and prostaglandin analogs are classified under Category C with uncertain safety. Selective LASER Trabeculoplasty (SLT) or Minimally Invasive Glaucoma Surgery (MIGS) may be options for pregnant glaucoma patients to reduce or stop unsafe glaucoma medications for the duration of the pregnancy. Since side effects during organogenesis are more dangerous, it is important to plan surgical or laser intervention before conception especially in uncontrolled glaucoma patients. Management of glaucoma during pregnancy is a delicate balance and may need collaboration between ophthalmologist, obstetrician, and neonatologist in high-risk pregnancies.,
Relaxin and glaucoma
Relaxin is a protein hormone presumed to be behind much of the IOP lowering effect in pregnancy. It is available commercially  and there is even a patent for its use, which expires in 2021. As mentioned in the accompanying study, relaxin has found experimental use in diseases such as cerebral cavernoma, osteosarcoma, and heart failure. In this study, the authors looked for the Relaxin receptor Relaxin/Insulin-Like Family Peptide Receptor 1 (RXFP1) in sections of the anterior segment of the eye and found it in inner uveal, corneoscleral and cribriform meshwork and Schlemm's canal endothelium.
Another recently studied Relaxin gene knockout (Rln -/-) mice showed that they had higher IOP, thicker corneas, larger endothelial cells, and lower endothelial cell density. They also found RXFP1 mRNA expression in the retina, cornea, sclera, and choroid, while RXFP2 was only in the cornea.
Even though Relaxin seems to have a potential to lower IOP, another study that used relaxin 2 in mice as eyedrops, intravitreally and intravenously found no lowering of IOP or change in arterial or venous diameter after 1 or 3 hours afterward.
Hope that newer targets for glaucoma medications would help us to medically treat uncontrolled glaucoma especially if a surgical option is not feasible.
| References|| |
Taradaj K, Ginda T, Maciejewicz P, Ciechanowicz P, Suchonska B, Hajbos M, et al
. Pregnancy and the eye. Changes in morphology of the cornea and the anterior chamber of the eye in pregnant woman. Ginekologia Polska 2018;89:695-9.
Brauner SC, Chen TC, Hutchinson BT, Chang MA, Pasquale LR, Grosskreutz CL. The course of glaucoma during pregnancy: A retrospective case series. Arch Ophthalmol 2006;124:1089-94.
Salim S. Glaucoma in pregnancy. Curr Opin Ophthalmol 2014;25:93-7.
Mathew S, Harris A, Ridenour CM, Wirostko BM, Burgett KM, Scripture MD, et al
. Management of glaucoma in pregnancy. J Glaucoma 2019;28:937-44.
Drake SC, Vajaranant TS. Evidence-based approaches to glaucoma management during pregnancy and lactation. Curr Ophthalmol Rep 2016;4:198-205.
Bani D, Yue SK, Bigazzi M. Clinical profile of relaxin, a possible new drug for human use. Curr Drug Saf 2009;4:238-49.
Zloto O, Skaat A, Fabian ID, Rosner M, Ziv H, Leshno A, et al
. The distribution of relaxin receptors in the anterior segment of primary open-angle glaucoma patients. Indian J Ophthalmol 2020;68:2117-20. [Full text]
Hampel U, Chinnery HR, Garreis F, Paulsen F, de Iongh R, Bui BV, et al
. Ocular phenotype of relaxin gene knock-out (Rln -/-
) mice. Curr Eye Res 2020;1-11. doi: 10.1080/02713683.2020.1737714. (just-accepted).
Hampel U, Träger K, Liu H, Teister J, Grus F, Prokosch-Willing V. Relaxin 2 fails to lower intraocular pressure and to dilate retinal vessels in rats. Int Ophthalmol 2019;39:847-51.